| Cover | Jun. 02, 2022 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | On June 2, 2022, ANI Pharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Prior 8-K”) announcing its decision to cease operations at its manufacturing plant located in Oakville, Ontario, Canada as part of ongoing initiatives to capture operational synergies following the Company’s acquisition of Novitium Pharma LLC. The Oakville manufacturing plant is expected to cease operations by the first quarter of 2023. As stated in the Prior 8-K, at the time the Prior 8-K was filed, the Company was unable to make a good faith estimate of the amount of charges and costs that may be incurred in connection with this closure. |
| Document Period End Date | Jun. 02, 2022 |
| Entity File Number | 001-31812 |
| Entity Registrant Name | ANI PHARMACEUTICALS, INC. |
| Entity Central Index Key | 0001023024 |
| Entity Tax Identification Number | 58-2301143 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 210 Main Street West |
| Entity Address, City or Town | Baudette |
| Entity Address, State or Province | MN |
| Entity Address, Postal Zip Code | 56623 |
| City Area Code | 218 |
| Local Phone Number | 634-3500 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock |
| Trading Symbol | ANIP |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
